Tuesday, November 03, 2015 9:08:17 AM
According to the National Institute of Mental Health (NIMH), major depression is one of the most common mental disorders in the United States. In 2013, an estimated 15.7 million individuals aged 18 or over – roughly 6.7 percent of all U.S. adults – had at least one major depressive episode. For these individuals, finding relief can be difficult. The American Academy of Family Physicians reports that up to two-thirds of all patients diagnosed with major unipolar depression will not respond to the first medication prescribed. If the second form of treatment also fails to produce a significant clinical improvement, the patient’s depression may be considered resistant to treatment. At this point, individuals have traditionally had extremely limited options for conquering this debilitating condition.
VistaGen Therapeutics, Inc. (OTCQB: VSTA), through the development of AV-101, is addressing this underserved indication. Earlier today, the company announced that it has taken a major step toward the eventual commercialization of its innovative drug candidate by dosing the first patient in its ongoing phase IIa study of AV-101 for treatment-resistant major depressive disorder (MDD). The study, which is being funded by the NIMH, is expected to enroll between 24 and 28 adult patients in order to evaluate the efficacy and safety of a single oral dose of AV-101 administered once daily for two weeks.
“We are pleased to have achieved this important milestone, notably advancing our AV-101 clinical development program, and we look forward to working closely with the esteemed leadership team at the NIMH,” Shawn Singh, chief executive officer of VistaGen, stated in a news release. “We believe that AV-101’s differentiated mechanism of action, oral availability, strong preclinical efficacy and excellent clinical safety profile support AV-101 as a potentially transformative treatment for millions of patients with MDD who are inadequately served by standard antidepressant therapies.”
In previous clinical testing, AV-101 has exhibited a host of sustained anti-depressant effects that exceed the effectiveness of currently available medications in the multi-billion dollar global antidepressant market – including serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). While SSRIs and SNRIs must be taken for several weeks before patients experience significant therapeutic benefits, AV-101 has demonstrated robust and rapid antidepressant effects similar to the benefits of ketamine without the high potential for abuse and psychosis-like behavioral side effects.
With its phase IIa study now underway, VistaGen expects top-line data in the first half of 2017. For prospective shareholders, the company’s progress toward the commercialization of its groundbreaking drug candidate makes it an intriguing investment opportunity in the coming months. Look for VistaGen to continue to benefit from its collaboration with the NIMH as it progresses toward a potentially transformative advancement in the treatment of MDD.
For more information on the company, visit www.vistagen.com
Recent VTGN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 09:00:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 09:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 09:00:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 09:00:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2024 08:07:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:53:06 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:49:59 PM
- Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update • Business Wire • 08/13/2024 08:21:00 PM
- Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024 • Business Wire • 08/06/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2024 08:27:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2024 08:34:14 PM
- Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine • Business Wire • 07/09/2024 12:30:00 PM
- Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year • Business Wire • 06/27/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:27:53 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/11/2024 08:27:09 PM
- Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update • Business Wire • 06/11/2024 08:20:00 PM
- U.S. Index Futures Fall Ahead of Federal Reserve Policy Meeting, Crude Oil Prices Decline • IH Market News • 06/11/2024 11:07:13 AM
- Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024 • Business Wire • 06/07/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:10:11 PM
- Vistagen to Present at the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 12:30:00 PM
- Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference • Business Wire • 05/23/2024 12:30:00 PM
- Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference • Business Wire • 05/07/2024 12:30:00 PM
- Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue • Business Wire • 04/25/2024 12:30:00 PM
- Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference • Business Wire • 04/09/2024 12:30:00 PM
- Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 • Business Wire • 04/01/2024 12:30:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM